Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernadette Mannaerts

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Clinical and Translational Science|May 13, 2021
First-in-human trial assessing the pharmacokinetic-pharmacodynamic profile of a novel recombinant human chorionic gonadotropin in healthy women and men of reproductive ageLars-Erik Broksø Kyhl, Christiane Hesse, Per Larsson, et al.
Human Reproduction (Oxford, England)|May 17, 2012
Prospective follow-up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcomeMaryse Bonduelle, Bernadette Mannaerts, Arthur Leader, et al.
Fertility and Sterility|March 31, 2012
A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle-stimulating hormoneRobert Boostanfar, Bernadette Mannaerts, Samuel Pang, et al.
Fertility and Sterility|December 3, 2013
Reply of the authorsGeorg Griesinger, Bernadette Mannaerts, Claus Yding Andersen, et al.
Fertility and Sterility|February 13, 2010
Corifollitropin alfa in a long GnRH agonist protocol: proof of concept trialHuman M Fatemi, Janine Oberyé, Biljana Popovic-Todorovic, et al.
Fertility and Sterility|October 3, 2013
Progesterone elevation does not compromise pregnancy rates in high responders: a pooled analysis of in vitro fertilization patients treated with recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in six trialsGeorg Griesinger, Bernadette Mannaerts, Claus Yding Andersen, et al.
Reproductive Biomedicine Online|November 10, 2021
Clinical outcomes of potential high responders after individualized FSH dosing based on anti-Müllerian hormone and body weightHana Višnová, Enrico Papaleo, Fernando Sánchez Martin, et al.
Reproductive Biomedicine Online|March 4, 2014
Short follicular phase of stimulation following corifollitropin alfa or daily recombinant FSH treatment does not compromise clinical outcome: a retrospective analysis of the Engage trialTonko Mardešič, Bernadette Mannaerts, Mostafa Abuzeid, et al.
Reproductive Biomedicine Online|February 5, 2019
Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and/or the need for additional preventive interventions: cumulative data over three stimulation cyclesManuel Fernández-Sánchez, Hana Visnova, Albert Yuzpe, et al.
Frontiers in Endocrinology|April 5, 2024
Corrigendum: Dose-dependent stimulation of human follicular steroidogenesis by a novel rhCG during ovarian stimulation with fixed rFSH dosingJane Alrø Bøtkjær, Stine Gry Kristensen, Hanna Ørnes Olesen, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Clinical and Translational Science|May 13, 2021
First-in-human trial assessing the pharmacokinetic-pharmacodynamic profile of a novel recombinant human chorionic gonadotropin in healthy women and men of reproductive ageLars-Erik Broksø Kyhl, Christiane Hesse, Per Larsson, et al.
Human Reproduction (Oxford, England)|May 17, 2012
Prospective follow-up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcomeMaryse Bonduelle, Bernadette Mannaerts, Arthur Leader, et al.
Fertility and Sterility|March 31, 2012
A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle-stimulating hormoneRobert Boostanfar, Bernadette Mannaerts, Samuel Pang, et al.
Fertility and Sterility|December 3, 2013
Reply of the authorsGeorg Griesinger, Bernadette Mannaerts, Claus Yding Andersen, et al.
Fertility and Sterility|February 13, 2010
Corifollitropin alfa in a long GnRH agonist protocol: proof of concept trialHuman M Fatemi, Janine Oberyé, Biljana Popovic-Todorovic, et al.
Fertility and Sterility|October 3, 2013
Progesterone elevation does not compromise pregnancy rates in high responders: a pooled analysis of in vitro fertilization patients treated with recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in six trialsGeorg Griesinger, Bernadette Mannaerts, Claus Yding Andersen, et al.
Reproductive Biomedicine Online|November 10, 2021
Clinical outcomes of potential high responders after individualized FSH dosing based on anti-Müllerian hormone and body weightHana Višnová, Enrico Papaleo, Fernando Sánchez Martin, et al.
Reproductive Biomedicine Online|March 4, 2014
Short follicular phase of stimulation following corifollitropin alfa or daily recombinant FSH treatment does not compromise clinical outcome: a retrospective analysis of the Engage trialTonko Mardešič, Bernadette Mannaerts, Mostafa Abuzeid, et al.
Reproductive Biomedicine Online|February 5, 2019
Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and/or the need for additional preventive interventions: cumulative data over three stimulation cyclesManuel Fernández-Sánchez, Hana Visnova, Albert Yuzpe, et al.
Frontiers in Endocrinology|April 5, 2024
Corrigendum: Dose-dependent stimulation of human follicular steroidogenesis by a novel rhCG during ovarian stimulation with fixed rFSH dosingJane Alrø Bøtkjær, Stine Gry Kristensen, Hanna Ørnes Olesen, et al.
Pageof 4